FDA-cleared profile

RadOncAI

Informai · Radiotherapy Planning Imaging · FDA-cleared (510(k))

An AI-guided planning tool that predicts radiation dose information for adult head-and-neck treatment planning.

Clinical role
RadOncAI provides AI-guided dose prediction from CT simulation and clinician-defined treatment-planning structures for adult head-and-neck malignant or benign disease.
Images and patients
Radiotherapy Planning Imaging · Head and neck
Key limitation
The software is not an autonomous treatment-decision or radiation-delivery system; a qualified radiation-oncology professional must review, revise, and approve its output.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?It provides AI-guided dose prediction for adult head-and-neck radiation-treatment planning.
  • Which scans and patients is it intended for?It is for adults with malignant or benign head-and-neck disease, using treatment-planning images and clinician-defined planning structures.
  • Who uses it?Radiation oncologists, medical physicists, and dosimetrists use it in a professional treatment-planning workflow.
  • What does the software produce, and what must the clinician do?It can produce treatment-planning information, including dose predictions. A radiation oncologist, physicist, or dosimetrist must review, revise, and approve it.
  • What is its most important limitation?It does not diagnose, make treatment decisions on its own, or deliver radiation.

Clinical takeaway. RadOncAI is a planning aid for a qualified radiation-oncology team. Human review, revision, and approval are required before use in treatment planning.

Evidence takeaway. The FDA material reports manufacturer-submitted validation in 500 adult head-and-neck cases with planning-structure acceptance testing and clinician review. It is not independent clinical validation or a guarantee of local performance.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
RadOncAI provides AI-guided dose prediction from CT simulation and clinician-defined treatment-planning structures for adult head-and-neck malignant or benign disease.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
RadOncAI provides AI-guided dose prediction from CT simulation and clinician-defined treatment-planning structures for adult head-and-neck malignant or benign disease.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
CT or MR treatment-planning images, target structures, organs-at-risk information, and other labeled planning inputs.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Contours, dose predictions, synthetic CT, registration, or other treatment-planning information described in the exact FDA labeling.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Radiation-oncology planning and review environments within hospitals or other professional treatment facilities.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Radiation oncologists, medical physicists, and dosimetrists.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
A radiation oncologist, physicist, or dosimetrist must review, revise, and approve the output; the software is not a diagnosis, autonomous treatment decision, or radiation-delivery system.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA decision material reports a 500-case adult head-and-neck radiotherapy validation with PTV and OAR acceptance testing and clinician review. These are manufacturer-submitted regulatory data, not independent clinical validation or a guarantee of local performance.
  • Exact FDA submission
  • Checked 2026-09-04

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA decision material reports a 500-case adult head-and-neck radiotherapy validation with PTV and OAR acceptance testing and clinician review. These are manufacturer-submitted regulatory data, not independent clinical validation or a guarantee of local performance.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Reported sensitivity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No exact-product, version-specific sensitivity endpoint was established for this submission in the evidence set.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No exact-product, version-specific specificity endpoint was established for this submission in the evidence set.

Validation cohort

500 patients

  • EndpointPatients in the manufacturer-submitted adult head-and-neck validation cohort
  • PopulationAdults with head-and-neck disease in the exact FDA validation package
  • Tested versionExact FDA submission release; version not separately stated in the public decision material

PTV equivalence tests meeting margin

9 tests

  • EndpointTests within the stated +/-300 cGy equivalence margin
  • PopulationThe 500-case adult head-and-neck validation cohort
  • Tested versionExact FDA submission release; version not separately stated in the public decision material

OAR non-inferiority metrics meeting margin

21 metrics

  • EndpointMetrics within the stated +300 cGy non-inferiority margin
  • PopulationThe 500-case adult head-and-neck validation cohort
  • Tested versionExact FDA submission release; version not separately stated in the public decision material

Clinical acceptability

100 percent

  • EndpointReviewer assessments judged clinically acceptable
  • Population50 cases reviewed by 3 board-certified radiation oncologists, 150 assessments
  • Tested versionExact FDA submission release; version not separately stated in the public decision material

OAR achievability

98.7 percent

  • EndpointReviewer assessments judged achievable for organs at risk
  • Population50 cases reviewed by 3 board-certified radiation oncologists, 150 assessments
  • Tested versionExact FDA submission release; version not separately stated in the public decision material

K253050 FDA evidence package for RadOncAI

  • DesignManufacturer-submitted retrospective regulatory validation with an independent clinician-review component; not independent clinical validation.
  • PopulationAdults with head-and-neck disease in the exact RadOncAI validation package.
  • Scopeexact submission
  • Tested versionExact FDA submission release; version not separately stated in the public decision material
  • Samplen=500
  • Sites2
  • IndependenceSponsor or vendor study

K253050

Evidence submitted for the exact FDA decision is not independent clinical validation. Local technical, clinical, privacy, security, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K253050 by native exact submission identifier. This does not exclude product-family, later, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS radiation-oncology material. Evaluate net planning or delivery value within the radiotherapy service line.
  • Service-level, not product-specific
  • Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Reviewed CMS material is not a product-specific price or coverage determination; do not infer reimbursement from FDA clearance.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: CT or MR treatment-planning images, target structures, organs-at-risk information, and other labeled planning inputs.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K253050: RadOncAI

  2. Routing

    Source context, not route validation: Accepts CT simulation, target, and organ-at-risk inputs and exports DICOM RT Dose to a compatible treatment-planning or DICOM-RT workflow.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA 510(k) decision material K253050: RadOncAI

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. Deployment details for the exact cleared configuration are not established in the public FDA decision material.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 ·

  4. Returned objects

    Source context, not route validation: Contours, dose predictions, synthetic CT, registration, or other treatment-planning information described in the exact FDA labeling.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K253050: RadOncAI

  5. Viewer/worklist/report

    Unresolved route: Contours, dose predictions, synthetic CT, registration, or other treatment-planning information described in the exact FDA labeling.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K253050: RadOncAI

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
Accepts CT simulation, target, and organ-at-risk inputs and exports DICOM RT Dose to a compatible treatment-planning or DICOM-RT workflow.
  • Exact FDA submission
  • Checked 2026-09-04
Training
Use by the qualified healthcare professionals identified for the exact labeled workflow; site-specific competency and training requirements remain to be established locally.
  • Exact FDA submission
  • Checked 2026-09-04

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K253050 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

Accepts CT simulation, target, and organ-at-risk inputs and exports DICOM RT Dose to a compatible treatment-planning or DICOM-RT workflow.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. A radiation oncologist, physicist, or dosimetrist must review, revise, and approve the output; the software is not a diagnosis, autonomous treatment decision, or radiation-delivery system.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-04

No exact-product price was found in the evidence set; productivity or value claims require local evidence.

Lifecycle monitoring

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes; exact monitoring thresholds and vendor commitments are unknown.

exact submission · checked 2026-09-04

Establish ownership for data quality, overrides, drift, incidents, recalls, and change control.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K253050
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Radiotherapy Planning Imaging
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Head and neck
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2026-06-18
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
26Fields reviewed
9Source classes checked
0Awaiting review PubMed leads
0Awaiting review trial leads
0Unreviewed FDA recall leads

This submission was added after the prior exact-submission extraction and remains queued for source review. Exact FDA decision material was reviewed for identity and labeled use. Optional literature, trial, and recall candidates were not promoted without exact product or version applicability; commercial, security, and performance claims remain unknown where not established. Automated exact-name discovery found 0 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared configuration was found in the evidence set. Obtain a written quote covering license or hardware basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, downtime, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Deployment: Not verified - checked 2026-09-04 - Exact FDA submission

    Deployment details for the exact cleared configuration are not established in the public FDA decision material.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not publicly available - checked 2026-09-04 - Exact FDA submission

    Security controls, hosting boundaries, audit behavior, identity management, and incident commitments for the exact configuration are not established in the public FDA decision material.

  • Installation timeline: Not yet reviewed
  • Monitoring: Not verified - checked 2026-09-04 - Exact FDA submission

    Post-deployment monitoring, drift thresholds, alerting, and revalidation commitments for the exact configuration require vendor and site confirmation.

6 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K253050: RadOncAI

    U.S. Food and Drug Administration - Published 2026-06-18 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  6. Radiation Oncology Model

    Centers for Medicare & Medicaid Services - Accessed 2026-09-02

    Scope: reimbursement, radiationTherapyPaymentContext

Research history

  1. K253050 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K252190

DeepBT Detector-Plus

Aitewan Biomedical Technology, Inc.

Authorized purpose: DeepBT Detector-Plus provides initial gross-tumor-volume contours on T1-weighted contrast-enhanced and optional T2-weighted MR images for radiation-treatment planning in adults with the labeled brain tumors.

Modality
Radiotherapy Planning Imaging
Anatomy
Brain tumors, including metastases, meningiomas, and acoustic neuromas
Decision
2026-04-10
FDA-cleared K252548

AI-Rad Companion Organs RT

Siemens Healthcare GmbH

Authorized purpose: AI-Rad Companion Organs RT VA70 automatically contours predefined structures, including known diagnosed brain metastases, on DICOM CT and MR images for radiation therapy planning; qualified users must review, edit and accept contours in suitable planning or contouring software, and the device is not intended for diagnosis.

Modality
Radiotherapy Planning Imaging
Anatomy
Head/neck, thorax, abdomen, pelvis; MR brain and male pelvis
Decision
2026-04-10
FDA-cleared K260509

AutoContour (RADAC V5)

Radformation, Inc.

Authorized purpose: AutoContour Model RADAC V5 assists radiation treatment planners with contouring and reviewing structures in medical images for radiation therapy treatment planning. It produces initial machine-learning contours for user review and modification; it does not independently approve a contour or treatment plan.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2026-03-19
FDA-cleared K252304

syngo.via RT Image Suite VC10

Varian Medical Systems, Inc.

Authorized purpose: syngo.via RT Image Suite VC10 provides three-dimensional and four-dimensional multimodality visualization, registration, fusion, contouring, and planning support for radiation-treatment preparation.

Modality
Radiotherapy Planning Imaging
Anatomy
Brain, pelvis, thorax, abdomen, targets, organs at risk, and moving tumors or organs
Decision
2026-03-18

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history